دورية أكاديمية
أعرض في EDS

Ursolic acid alleviates airway-vessel remodeling and muscle consumption in cigarette smoke-induced emphysema rats.

التفاصيل البيبلوغرافية
العنوان: Ursolic acid alleviates airway-vessel remodeling and muscle consumption in cigarette smoke-induced emphysema rats.
المؤلفون: Lin L; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China., Hou G; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China., Han D; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China., Yin Y; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China., Kang J; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China., Wang Q; Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, China. qywang2002@hotmail.com.
المصدر: BMC pulmonary medicine [BMC Pulm Med] 2019 Jun 06; Vol. 19 (1), pp. 103. Date of Electronic Publication: 2019 Jun 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001]-
مواضيع طبية MeSH: Airway Remodeling/*drug effects , Cigarette Smoking/*adverse effects , Muscle, Skeletal/*pathology , Pulmonary Emphysema/*prevention & control , Signal Transduction/*drug effects , Triterpenes/*pharmacology, Animals ; Atrophy/etiology ; Atrophy/prevention & control ; Cyclooxygenase Inhibitors/pharmacology ; Epithelial-Mesenchymal Transition/physiology ; Insulin-Like Growth Factor I/metabolism ; Male ; Pulmonary Emphysema/etiology ; Rats ; Rats, Wistar ; Smad2 Protein/metabolism ; Smoke/adverse effects ; Transforming Growth Factor beta1/metabolism ; Ursolic Acid
مستخلص: Background: This study assessed the effects of ursolic acid (UA) on airway-vessel remodeling and muscle atrophy in cigarette smoke (CS)-induced emphysema rats and investigated potential underlying mechanisms.
Methods: Emphysema was induced in a rat model with 3 months of CS exposure. Histology and immunohistochemistry (IHC) stains were used to assess airway-vessel remodeling and muscle atrophy-associated changes. Levels of cleaved-caspase3, 8-OHdG, and S100A4 were measured in airways and associated vessels to evaluate cell apoptosis, oxidant stress, epithelial-to-mesenchymal transition (EMT), and endothelial-to-mesenchymal transition (EndMT)-associated factors. Western blot and/or IHC analyses were performed to measure transforming growth factor-beta 1(TGF-β1)/Smad2.3, alpha-smooth muscle actin (α-SMA), and insulin-like growth factor 1 (IGF1) expression. We also gave cultured HBE and HUVEC cells Cigarette Smoke Extract (CSE) administration and UA intervention. Using Western blot method to measure TGF-β1/Smad2.3, α-SMA, S100A4, and IGF1 molecules expression.
Results: UA decreased oxidant stress and cell apoptosis in airway and accompanying vascular walls of cigarette smoke-induced emphysema model rats. UA alleviated EMT, EndMT, changes associated with airway-vessel remodeling and muscle atrophy. The UA effects were associated with IGF1 and TGF-β1/Smad2.3 pathways.
Conclusions: UA reduced EMT, EndMT, airway-vessel remodeling, and musculi soleus atrophy in CS-induced emphysema model rats at least partly through IGF1 and TGF-β1/Smad2.3 signaling pathways.
References: Annu Rev Med. 2003;54:113-29. (PMID: 12359824)
Am J Respir Crit Care Med. 2003 Feb 15;167(4):544-9. (PMID: 12446268)
Thorax. 2003 Sep;58(9):752-6. (PMID: 12947130)
FEBS Lett. 2004 May 21;566(1-3):55-9. (PMID: 15147868)
Lancet. 2004 Aug 21-27;364(9435):709-21. (PMID: 15325838)
Thorax. 2005 Feb;60(2):106-13. (PMID: 15681497)
Am J Respir Crit Care Med. 2007 Oct 15;176(8):753-60. (PMID: 17575095)
Lancet. 2007 Sep 1;370(9589):741-50. (PMID: 17765523)
Am J Physiol Lung Cell Mol Physiol. 2009 Apr;296(4):L648-56. (PMID: 19201816)
COPD. 2009 Aug;6(4):234-41. (PMID: 19811381)
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1114-22. (PMID: 20622027)
Am J Pathol. 2011 Jul;179(1):125-33. (PMID: 21703398)
Am J Physiol Lung Cell Mol Physiol. 2012 Feb 1;302(3):L325-33. (PMID: 22003087)
PLoS One. 2012;7(6):e39736. (PMID: 22768115)
J Appl Physiol (1985). 2013 May;114(9):1329-39. (PMID: 22936724)
J Neuroimmunol. 2013 Jan 15;254(1-2):69-75. (PMID: 23031832)
Cell Biochem Biophys. 2013 Nov;67(2):219-34. (PMID: 23975597)
Chest. 2013 Sep;144(3):1026-1032. (PMID: 24008953)
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. (PMID: 24355635)
J Mol Cell Cardiol. 2014 Feb;67:103-11. (PMID: 24389342)
J Pharmacol Exp Ther. 2014 May;349(2):229-38. (PMID: 24563530)
BMC Complement Altern Med. 2014 Apr 26;14:140. (PMID: 24766819)
Pulm Pharmacol Ther. 2014 Dec;29(2):144-55. (PMID: 25316209)
J Biol Chem. 2015 Feb 6;290(6):3277. (PMID: 25661316)
PLoS One. 2015 Mar 19;10(3):e0119797. (PMID: 25790295)
Cardiovasc Ther. 2015 Aug;33(4):161-7. (PMID: 25903305)
Mol Cell Biochem. 2015 Sep;407(1-2):197-207. (PMID: 26045172)
Lab Invest. 2015 Oct;95(10):1157-73. (PMID: 26192086)
Int Immunopharmacol. 2015 Sep;28(1):707-14. (PMID: 26258626)
J Bras Pneumol. 2015 Sep-Oct;41(5):415-21. (PMID: 26578132)
Life Sci. 2016 Jan 1;144:208-17. (PMID: 26656263)
J Chem Neuroanat. 2016 Jan;71:41-9. (PMID: 26686287)
Ann Am Thorac Soc. 2016 Mar;13(3):334-41. (PMID: 26700501)
J Diabetes Complications. 2016 May-Jun;30(4):573-9. (PMID: 26861949)
Respir Res. 2016 Feb 22;17:20. (PMID: 26898357)
Respirology. 2016 Aug;21(6):984-94. (PMID: 27028849)
Chron Respir Dis. 2016 Aug;13(3):297-311. (PMID: 27056059)
Recent Pat Inflamm Allergy Drug Discov. 2016;10(1):21-33. (PMID: 27531153)
Respirology. 2017 Jan;22(1):133-140. (PMID: 27614607)
Int J Chron Obstruct Pulmon Dis. 2016 Sep 22;11:2359-2367. (PMID: 27703346)
Int J Chron Obstruct Pulmon Dis. 2016 Sep 29;11:2447-2455. (PMID: 27729785)
Neurochem Res. 2017 Feb;42(2):337-346. (PMID: 27734181)
PLoS One. 2016 Nov 18;11(11):e0166388. (PMID: 27861515)
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):327-341. (PMID: 27897418)
Lancet. 2016 Dec 3;388(10061):2740-2741. (PMID: 27924774)
Oncotarget. 2017 Apr 4;8(14):22625-22639. (PMID: 28186986)
Int J Chron Obstruct Pulmon Dis. 2017 Feb 13;12:551-560. (PMID: 28243075)
Int J Oncol. 2017 Apr;50(4):1330-1340. (PMID: 28259944)
Int J Chron Obstruct Pulmon Dis. 2017 Feb 20;12:581-587. (PMID: 28260872)
Respir Investig. 2017 Mar;55(2):104-113. (PMID: 28274525)
Pulm Pharmacol Ther. 2017 Jun;44:111-121. (PMID: 28347799)
Biomed Res Int. 2017;2017:6510198. (PMID: 28421197)
Lancet. 2018 Apr 28;391(10131):1706-1717. (PMID: 29650248)
Biol Reprod. 2018 Nov 1;99(5):1100-1112. (PMID: 29893818)
المشرفين على المادة: 0 (Cyclooxygenase Inhibitors)
0 (Smad2 Protein)
0 (Smoke)
0 (Transforming Growth Factor beta1)
0 (Triterpenes)
67763-96-6 (Insulin-Like Growth Factor I)
تواريخ الأحداث: Date Created: 20190608 Date Completed: 20191211 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6555740
DOI: 10.1186/s12890-019-0826-6
PMID: 31170951
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2466
DOI:10.1186/s12890-019-0826-6